{"prompt": "['Alliance A221504', 'A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral', 'Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer', 'Eligibility Criteria (see Section 3.2)', 'Required Initial Laboratory Values', 'Advanced (stage IIIB or IV) non-small cell lung cancer. See 3.2.1', 'Absolute neutrophil', '> 1500/mm\u00b3', 'No known presence of known EGFR or EML4-ALK driver mutations in the tumor', 'count (ANC)', \"Started first-line systemic therapy of the investigator's choice within 12 weeks prior\", 'Platelet Count > 100,000/mm\u00b3', 'to registration, or planning to initiate first-line systemic therapy of the', 'Calc. Creatinine > 60 mL/min*', \"investigator's choice within 4 weeks after registration. See 3.2.3.\", 'No prior systemic therapy for advanced NSCLC (other than current treatment). See', 'Clearance (see', '3.2.4.', 'Alliance website)', 'No current or prolonged recent use of mixed opioid agonists/antagonists or other', 'Total Bilirubin', '1.2 x ULN**', 'opioid antagonists. See 3.2.5', 'No methadone within 4 weeks prior to registration.', 'AST and ALT', 'VI 2.5 x ULN', 'Patients must have used opioid medication(s) for pain at some time in the 4 weeks', 'prior to registration. See 3.2.7.', 'Expected survival > 3 months.', '* Calculated using the Cockcroft-Gault', 'No concurrently active second invasive malignancies except non-melanoma skin', 'formula', 'cancer. See 3.2.9.', \"**Unless due to Gilbert's disease\", 'No history of gastrointestinal obstruction or conditions that increase the risk of', 'gastrointestinal obstruction, perforation, bleeding or impairment of the', 'gastrointestinal wall. No abdominal surgery within 60 days of registration.', 'No acute gastrointestinal conditions. See 3.2.11', 'No conditions that may compromise blood-brain barrier permeability. See 3.2.12', 'No history of myocardial infarction VI 6 months prior to registration. See 3.2.13.', 'No severe hepatic impairment (Child-Pugh class C), or acute liver disease.', 'No known serious or severe hypersensitivity reaction to naloxegol or any of its', 'excipients', 'No concurrent use of moderate/strong CYP3A4 inhibitors, strong CYP3A4', 'inducers, or other opioid antagonists or mixed agonists/antagonists. See 3.2.16.', 'Not pregnant and not nursing. See 3.2.17.', 'Age > 18 years', 'ECOG Performance Status 0-2', 'Schema', '1 Cycle = 3 weeks during the first year of treatment', '1', 'Cycle = 3 months during the second year of treatment', 'R', 'Naloxegol 12.5 mg', 'A', 'orally once daily', 'N', 'D', 'Naloxegol 25 mg', 'O', 'orally once daily', 'M', 'I', 'Placebo', 'Z', 'orally once daily', 'E', 'Treatment is to continue for up to 2 years, but it can be discontinued for unacceptable adverse events.', 'Clinic visits will take place at 3 and 6 weeks and then every 6 weeks for 1 year following the start of', 'treatment. Patients will then be followed every 3 months until 2 years after the start of treatment.', 'Administration of standard opioids and other analgesics to control pain adequately will be permitted in all', 'patients at the discretion of the treating physician.', 'Please refer to the full protocol text for a complete description of the eligibility criteria and', 'treatment plan.', '4', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'TABLE OF CONTENTS', 'Section', 'Page', '1.0', 'BACKGROUND', '7', '1.1', 'Rationale for Proposed Study', '7', '1.2', 'Rationale for selecting lung cancer', '7', '1.3', 'Rationale for selecting feasibility and safety as the primary endpoint:', '8', '1.4', 'Rationale for estimating change in HRQoL in the current study', '8', '1.5', 'Rationale for selecting baseline levels/presence/absence of pain, opioid use and peripheral', 'adverse effects of opioids:', '9', '1.6 Rationale for a 3-arm study design including placebo and 2 dose arms of study drug:', '11', '1.7', 'Basic and pre-clinical studies', '12', '1.8', 'Naloxegol and other PAMORAs', '14', '1.9', 'Study Hypotheses', '15', '1.10', 'How this pilot study will provide essential data for a future, more definitive study, and its', 'possible design:', '15', '2.0', 'OBJECTIVES', '16', '2.1', 'Primary objective', '16', '2.2', 'Secondary objective(s)', '16', '2.3', 'Correlative science objective', '16', '3.0', 'PATIENT SELECTION', '16', '3.1', 'On-Study Guidelines', '16', '3.2', 'Eligibility Criteria', '17', '4.0', 'PATIENT REGISTRATION', '20', '4.1', 'CTEP / DCP Investigator Registration Procedures', '20', '4.2', 'CTSU Site Registration Procedures', '21', '4.3', 'Patient Registration Requirements', '23', '4.4', 'Patient Registration/Randomization Procedures', '23', '4.5', 'Registration to Correlative and Companion Studies', '24', '4.6', 'Stratification Factors', '24', '4.7', 'Procedures for Double-Blinding the Treatment Assignment', '24', '5.0', 'STUDY CALENDAR', '25', '6.0', 'DATA AND SPECIMEN SUBMISSION', '26', '6.1', 'Data Collection and Submission', '26', '6.2', 'Specimen collection and submission', '28', '7.0', 'TREATMENT PLAN/INTERVENTION', '31', '7.1', 'Naloxegol/ Placebo', '31', '7.2', 'First-line systemic therapy.', '32', '7.3', 'Opioids', '32', '8.0', 'DOSE AND TREATMENT MODIFICATIONS & UNBLINDING', '32', '8.1', 'Ancillary therapy, concomitant medications, and supportive care', '32', '8.2', 'Dose Modifications', '34', '8.3', 'Unblinding Procedures', '35', '9.0', 'ADVERSE EVENTS', '36', '9.1', 'Routine adverse event reporting', '36', '9.2', 'CTCAE Routine Reporting Requirements', '37', '5', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}